Antithrombotic therapy and cavernoma bleeding: does vascular border zone localization matter?

Area of Science:

• Neurology
• Neurosurgery
• Vascular Malformations

Background:

• Hemorrhagic events in cerebral cavernous malformations (CCMs) contribute significantly to patient morbidity and mortality.
• Identifying risk factors for CCM bleeding is critical for guiding clinical and surgical management strategies.

Purpose of the Study:

• To investigate potential and known risk factors associated with bleeding in patients diagnosed with cerebral cavernous malformations.
• To evaluate the influence of demographic, clinical, and imaging characteristics on CCM hemorrhage risk.

Main Methods:

• A retrospective, observational, single-center study was conducted.
• Data from 143 patients with cerebral cavernous malformations were analyzed.
• Evaluated factors included age, gender, smoking, hypertension, antithrombotic use, diabetes, seizures, cavernoma shape, size changes, and lesion location.

Main Results:

• Antithrombotic medication use was associated with a significantly lower frequency of hemorrhage (p=0.012).
• Irregular cavernoma shape on MRI and cavernoma growth during follow-up were independently associated with increased bleeding risk (p<0.001 and p=0.002, respectively).
• Male gender was also linked to a higher bleeding risk (OR: 2.114, p=0.037).

Conclusions:

• Antithrombotic therapy appears to reduce hemorrhage risk in CCM patients.
• Irregular cavernoma morphology and lesion growth are significant predictors of bleeding events.
• Further research is warranted to elucidate the complex factors influencing CCM hemorrhage.